Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn’s Disease

Lee, Scott D.; Singla, Anand; Harper, Jason; Barahimi, Mitra; Jacobs, Jeffrey; Kamp, Kendra; Clark‐Snustad, Kindra

doi:10.1007/s10620-022-07444-5

Cited by 7 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tofacitinib is a reversible Janus kinase (JAK) inhibitor used in the treatment of ulcerative colitis (UC). 1,2 Patients taking tofacitinib and other JAK inhibitors are at increased risk of a primary infection and latent reactivation of the varicella-zoster virus (VZV), otherwise known as shingles. Other independent risks of VZV infection include age, Asian heritage, and immune-mediated diseases such as UC.…”

Section: Introductionmentioning

confidence: 99%

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

Thomas,

Moskow,

Garza

et al. 2023

ACG Case Rep J

View full text Add to dashboard Cite

Shingles, also known as herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV). The risk of developing shingles increases with age, as well as in patients with weakened immune systems. Tofacitinib is a reversible Janus kinase inhibitor that suppresses the immune system and is used to treat autoimmune diseases, such as ulcerative colitis. Recombinant VZV vaccine is recommended for individuals taking tofacitinib and is highly effective at reducing the risk of shingles. This case report describes a patient with severe, refractory ulcerative colitis who developed shingles while on tofacitinib, despite prior vaccination with the recombinant VZV vaccine.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

Thomas,

Moskow,

Garza

et al. 2023

ACG Case Rep J

View full text Add to dashboard Cite

show abstract

“…In this issue of Digestive Diseases and Sciences, Lee et al [7] reported another cohort of patients with CD treated with tofacitinib in a real-world setting. Their study enrolled 44 patients, among whom 35 were assessed for efficacy.…”

mentioning

confidence: 99%

Tofacitinib: A Small Molecule for Biologic-Refractory Crohn’s Disease?

Uzzan

2022

Dig Dis Sci

View full text Add to dashboard Cite

Treating paediatric Crohn’s disease is challenging but new treatments hold promise

Nie

2024

Drugs Ther Perspect

View full text Add to dashboard Cite

Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn’s Disease

Cited by 7 publications

References 13 publications

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

Tofacitinib: A Small Molecule for Biologic-Refractory Crohn’s Disease?

Treating paediatric Crohn’s disease is challenging but new treatments hold promise

Contact Info

Product

Resources

About